{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:35:24Z","timestamp":1785256524934,"version":"3.55.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1097\/md.0000000000001626","type":"journal-article","created":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T22:21:00Z","timestamp":1443046860000},"page":"e1626","source":"Crossref","is-referenced-by-count":22,"title":["Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan"],"prefix":"10.1097","volume":"94","author":[{"given":"Yi-Ping","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Huang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Pin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiu-Mei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzeon-Jye","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzeng-Ji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muh-Hwa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-39-20210226","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN, 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"R2-39-20210226","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4143\/crt.2012.44.3.173","article-title":"Metachronous double primary cancer after diagnosis of gastric cancer","volume":"44","author":"Kim","year":"2012","journal-title":"Cancer Res Treat"},{"key":"R3-39-20210226","first-page":"183","article-title":"Multiple primary cancers in the stomach and another organ: frequency and the effects on prognosis","volume":"15","author":"Yoshino","year":"1985","journal-title":"Jpn J Clin Oncol"},{"key":"R4-39-20210226","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/1471-2407-13-394","article-title":"Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer","volume":"13","author":"Kim","year":"2013","journal-title":"BMC Cancer"},{"key":"R5-39-20210226","first-page":"203","article-title":"A case-control study of leukaemia as a second primary malignancy following ovarian and breast neoplasms","volume":"78","author":"Mehnert","year":"1986","journal-title":"IARC Sci Publications"},{"key":"R6-39-20210226","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1023\/A:1008356806417","article-title":"Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada\u2013Clinical Trials Group (NCIC-CTG)","volume":"11","author":"Dent","year":"2000","journal-title":"Ann Oncol"},{"key":"R7-39-20210226","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bjc.1987.201","article-title":"Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis: a population-based cohort study","volume":"56","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"key":"R8-39-20210226","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/CEJ.0b013e3283240474","article-title":"Second neoplasms after invasive and borderline ovarian cancer","volume":"18","author":"Levi","year":"2009","journal-title":"Eur J Cancer Prev"},{"key":"R9-39-20210226","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0959-8049(99)00244-0","article-title":"Overestimated risk of second primary malignancies in ovarian cancer patients","volume":"36","author":"Bergfeldt","year":"2000","journal-title":"Eur J Cancer"},{"key":"R10-39-20210226","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1377\/hlthaff.22.3.61","article-title":"Taiwan's new national health insurance program: genesis and experience so far","volume":"22","author":"Cheng","year":"2003","journal-title":"Health Aff (Millwood"},{"key":"R11-39-20210226","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00404-010-1585-z","article-title":"Second primary cancers following borderline ovarian tumors","volume":"283","author":"Sanci","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"R12-39-20210226","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2008.01.032","article-title":"Increased risk of second cancer among patients with ovarian borderline tumors","volume":"109","author":"Bouchardy","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R13-39-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.coc.0000231364.89294.13","article-title":"Epithelial ovarian cancer and low malignant potential (LMP) tumors associated with a lower incidence of second primary breast cancer","volume":"30","author":"Hunter","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"R14-39-20210226","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0020-7292(00)00357-X","article-title":"Prior, synchronous and secondary malignancies in women with ovarian cancer","volume":"73","author":"Kehoe","year":"2001","journal-title":"Int J Gynaecol Obstet"},{"key":"R15-39-20210226","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/sj.bjc.6690002","article-title":"Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms","volume":"79","author":"Levi","year":"1999","journal-title":"Br J Cancer"},{"key":"R16-39-20210226","first-page":"280","article-title":"A second primary malignancy in a cohort of patients with epithelial ovarian cancer: characteristics of diagnosis","volume":"19","author":"Fishman","year":"1998","journal-title":"Eur J Gynaecol Oncol"},{"key":"R17-39-20210226","first-page":"269","article-title":"Familial risk factors for a second primary malignancy in endometrial or ovarian carcinoma","volume":"21","author":"Shiromizu","year":"1995","journal-title":"J Obstet Gynaecol (Tokyo 1995"},{"key":"R18-39-20210226","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ijc.2910390506","article-title":"Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries","volume":"39","author":"Kaldor","year":"1987","journal-title":"Int J Cancer"},{"key":"R19-39-20210226","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0090-8258(82)90074-9","article-title":"Secondary neoplasms in treated ovarian cancer","volume":"13","author":"Kagan","year":"1982","journal-title":"Gynecologic Oncol"},{"key":"R20-39-20210226","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/jnci\/61.5.1195","article-title":"Second primary neoplasms following ovarian cancer","volume":"61","author":"Reimer","year":"1978","journal-title":"J Natl Cancer Instit"},{"key":"R21-39-20210226","first-page":"283","article-title":"Multiple threat: second primary malignancies in patients with ovarian carcinoma treated with radiation and chemotherapy","volume":"78","author":"Masterson","year":"1977","journal-title":"J Kansas Med Soc"},{"key":"R22-39-20210226","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/GIM.0b013e3181d38f2f","article-title":"Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2","volume":"12","author":"Petrucelli","year":"2010","journal-title":"Genet Med"},{"key":"R23-39-20210226","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"key":"R24-39-20210226","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J Natl Cancer Instit"},{"key":"R25-39-20210226","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO.2013.50.6055","article-title":"Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study","volume":"32","author":"Daniels","year":"2014","journal-title":"J Clin Oncol"},{"key":"R26-39-20210226","doi-asserted-by":"crossref","first-page":"dju091","DOI":"10.1093\/jnci\/dju091","article-title":"Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis","volume":"106","author":"Friebel","year":"2014","journal-title":"J National Cancer Instit"},{"key":"R27-39-20210226","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/cncr.28662","article-title":"BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts","volume":"120","author":"Lucas","year":"2014","journal-title":"Cancer"},{"key":"R28-39-20210226","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/bjc.2011.371","article-title":"Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition","volume":"105","author":"Tsilidis","year":"2011","journal-title":"Brit J Cancer"},{"key":"R29-39-20210226","first-page":"379","article-title":"Life style and risk of development of breast and ovarian cancer","volume":"19","author":"Pieta","year":"2012","journal-title":"Ann Agric Environ Med"},{"key":"R30-39-20210226","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/bjc.1987.40","article-title":"Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide","volume":"55","author":"Haas","year":"1987","journal-title":"Br J Cancer"},{"key":"R31-39-20210226","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ijc.27597","article-title":"Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients","volume":"132","author":"Lo","year":"2013","journal-title":"Int J Cancer"},{"key":"R32-39-20210226","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cgh.2010.10.014","article-title":"Increased risk for malignant neoplasms among patients with cirrhosis","volume":"9","author":"Kalaitzakis","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R33-39-20210226","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.rmed.2011.12.009","article-title":"Chronic obstructive pulmonary disease and cancer risk: a Danish nationwide cohort study","volume":"106","author":"Kornum","year":"2012","journal-title":"Respir Med"},{"key":"R34-39-20210226","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/030089169007600205","article-title":"5-Fluorouracil carcinogenesis in BALB\/c mice","volume":"76","author":"Cavaliere","year":"1990","journal-title":"Tumori"},{"key":"R35-39-20210226","first-page":"25","article-title":"IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: general remarks on the substances considered.","volume":"16","year":"1978","journal-title":"IARC Monogr Eval Carcinog Risk Chem Man"},{"key":"R36-39-20210226","first-page":"559","article-title":"Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study","volume":"20","author":"Drucker","year":"2000","journal-title":"Anticancer Res"},{"key":"R37-39-20210226","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/jnci\/djh006","article-title":"Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer","volume":"96","author":"Kirchhoff","year":"2004","journal-title":"J Natl Cancer Instit"},{"key":"R38-39-20210226","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jnci\/djh008","article-title":"BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer","volume":"96","author":"Niell","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R39-39-20210226","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1007\/s11033-013-2775-0","article-title":"Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families","volume":"40","author":"Rudnicka","year":"2013","journal-title":"Mol Biol Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000001626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:50:42Z","timestamp":1620960642000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201509040-00039"}},"subtitle":["A Nationwide Population-Based Study"],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":39,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001626","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}